Pharmasum is in a strong position to capitalise on identifying and designing proprietary inhibitors of DYRK1A with patent rights and access to strong industrial experience in drug design at the University of Tromsø, Norway.

The company’s cutting edge design and translational medicine engine offer a unique structure-based drug discovery process:

  Competences and facilities available for target - drug interactions

  •     X-ray crystallography
  •     Biophysical measurements (600 and 400 MHz NMR, ITC)
  •     More than 11 proprietary X-ray structures of enzyme: ligand (1.8Å resolution)

  Supercomputing facilities running Schrödinger modelling software
This has achieved a hit to lead with fewer than 40 compounds synthesized in the first lean project.